HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis
Open Access
- 3 January 2024
- journal article
- review article
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 26 (1) , 1-13
Abstract
Purpose of Review: Bruton tyrosine kinase inhibitors (BTKIs) are immunosuppressive cancer therapies approved for the treatment of various mature B-cell malignancies. Hepatitis B virus reactivation (HBVr) is a known complication in patients with chronic or past HBV infection undergoing immunosuppressive chemotherapy. The present work aims to establish the correlation between HBVr and patients receiving BTKIs. Recent Findings: This review included 18 studies. The overall incidence of HBVr was found to be 6.6% in patients with past HBV infections who received ibrutinib. Fourteen cases of HBVr were associated with ibrutinib (two occult hepatitis B infections and twelve past HBV infections). One case of HBV past infection was associated with zanubrutinib, and three cases were recorded for acalabrutinib (one chronic HBV and two past HBV). Most incidents occurred in males older than 60 years within the first year after initiating BTKIs. Three reported cases documented HBVr after discontinuing ibrutinib and zanubrutinib. Two deaths caused by HBVr in patients with past HBV infections were recorded (one for each of acalabrutinib and ibrutinib). Remarkably, HBV antiviral treatment normalized liver functions and eliminated serum HBV in most cases. It was reported that false negativity of HBsAg following reactivation occurred in two cases: one case was attributed to HBsAg escape mutations, and the other to the hook effect. Summary: Our findings show that HBVr risk is intermediate in patients with past HBV infections who receive ibrutinib. Universal anti-HBV prophylaxis before initiating ibrutinib may be an option.Keywords
Funding Information
- Al-Azhar University
This publication has 30 references indexed in Scilit:
- Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive TherapyThe Journal of Infectious Diseases, 2017
- Is HBV prophylaxis required during CLL treatment with ibrutinib?Leukemia & Lymphoma, 2017
- Severe hepatitis B virus reactivation related to ibrutinib monotherapyAnnals of Hematology, 2017
- Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?Leukemia Research, 2016
- Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)The Lancet Infectious Diseases, 2016
- PTU-101 Rituximab and hepatitis b: are we doing it right?2015
- American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug TherapyGastroenterology, 2015
- Hepatitis B Reactivation and Rituximab in the Oncology PracticeThe Oncologist, 2010
- Statements from the Taormina expert meeting on occult hepatitis B virus infectionJournal of Hepatology, 2008
- Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOPAnnals of Hematology, 2004